Registered title, quoted from ClinicalTrials.gov
Study on the Treatment of Hepatitis B Virus(HBV) Infected Individuals With Peginterferon α-2b Combined With NA.
An open trial on hepatocellular carcinoma, registered on ClinicalTrials.gov. Led by Xiangya Hospital; 1 other hospital on this site is listed as study site.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 2
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Lead sponsorXiangya Hospital中南大学湘雅医院ChangshaHospital page
- Study siteThird Affiliated Hospital of Sun Yat-sen University中山大学附属第三医院GuangzhouHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06746701, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 4
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (4 points)Hide the checklist
18 years to 65 years; sex: all
Registered eligibility fields
ALT(Alanine Aminotransferase) greater than 10 times the upper limit of normal, total bilirubin greater than 2 times the upper limit of normal;
Exclusion criterion 3
Neutrophil count < 1.5 x 10\^9/L or platelet count < 80 x 10\^9/L;
Exclusion criterion 5
HIV co-infection;
Exclusion criterion 13
Negative urine or serum pregnancy test within 24 hours before the first dose (for women of childbearing age);
Inclusion criterion 5
Pregnant or planning to become pregnant within 2 years;
Exclusion criterion 11
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06746701, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Age18-65 years (inclusive of 18 and 65), no restriction on gender;
- HBsAg positive history for at least 6 months;
- Family history of liver cancer [including first-degree and second-degree relatives; first-degree relatives are parents, children, and siblings (same parents), while second-degree relatives are uncles, aunts, grandparents, and great-grandparents; a family history of liver cancer means that one or more first-degree or second-degree relatives have had liver cancer];
- Planning to or already receiving treatment with Peginterferon alpha-2b in combination with nucleoside (acid) analogs, or receiving nucleoside (acid) analogs treatment alone;
- Negative urine or serum pregnancy test within 24 hours before the first dose (for women of childbearing age);
- Willing to receive treatment and sign an informed consent form.
Exclusion Criteria:
- Allergy to interferon;
- History of using telbivudine for antiviral treatment;
- ALT(Alanine Aminotransferase) greater than 10 times the upper limit of normal, total bilirubin greater than 2 times the upper limit of normal;
- Decompensated liver cirrhosis;
- Neutrophil count < 1.5 x 10\^9/L or platelet count < 80 x 10\^9/L;
- Presence of severe lesions in vital organs such as the cardiovascular, pulmonary, renal, brain, and fundus;
- Those with autoimmune diseases, psychiatric disorders, poorly controlled diabetes, or thyroid dysfunction (hyperthyroidism or hypothyroidism);
- Confirmed or suspected liver cancer or other malignant tumors;
- Post-organ transplant or preparing for organ transplantation;
- Currently using immunosuppressants;
- Pregnant or planning to become pregnant within 2 years;
- Alcohol or drug addicts;
- HIV co-infection;
- Other conditions deemed unsuitable for interferon use by the attending physician.
Quoted from ClinicalTrials.gov, NCT06746701, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06746701, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.